Showing a significantly higher expression in both the nucleus and cytoplasm of breast and ovarian cancer cells compared to benign tissues, it activates cell proliferation and accelerates migration and invasion through ER-independent and ER-dependent pathways (Wu et al. 2016). This evidence concerns the gene ESR1 and ovarian cancer.